Aurobindo Pharma completes sale of US subsidiary's Natrol to New Mountain

Drug firm Aurobindo Pharma said it has completed the sale of Natrol LLC, a wholly-owned unit of its US-based subsidiary, to private equity firm New Mountain Capital

Topics
Aurobindo Pharma | Indian pharma companies

Press Trust of India  |  New Delhi 

paracetamol, pharma, drugs, medicine, health
Representative photo of pills

Drug firm on Tuesday said it has completed the sale of Natrol LLC, a wholly-owned unit of its US-based subsidiary, to private equity firm New Mountain Capital.

In October this year, the company had announced that it had inked a pact to divest Natrol LLC to private equity firm New Mountain Capital for USD 550 million.

"The aforesaid transaction has been completed on November 30, 2020," said in a regulatory filing.

had acquired Natrol in December 2014.

Natrol's annual sales for the 12 months ended March 31, 2020, stood at around USD 157 million.

Earlier, Aurobindo Pharma Managing Director N Govindarajan had said that proceeds from Natrol's divestiture will be used to reduce debt and other new strategic initiatives.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Aurobindo Pharma
First Published: Tue, December 01 2020. 12:56 IST
RECOMMENDED FOR YOU